Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: Conceptual framework and example

Alzheimer's and Dementia

Volumn 10, Issue 2, 2014, Pages 152-161

  Leoutsakos, Jeannie Marie S ^a   Bartlett, Alexandra L ^b   Forrester, Sarah N ^a   Lyketsos, Constantine G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b South River High School   (United States)

Author keywords

Alzheimer's disease; Biomarker enrichment; Dementia; Random effects; Simulation; Statistical power; Trajectory

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; CONCEPTUAL FRAMEWORK; DEMENTIA; HUMAN; PREDICTIVE VALUE; PREVENTION STUDY; PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION;

ALZHEIMER'S DISEASE; BIOMARKER ENRICHMENT; DEMENTIA; RANDOM EFFECTS; SIMULATION; STATISTICAL POWER; TRAJECTORY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; COMPUTER SIMULATION; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; NAPROXEN; PYRAZOLES; SULFONAMIDES;

EID: 84897568536     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.05.1776     Document Type: Article

References (51)

1. E.M. Reiman, J.B. Langbaum, and P.N. Tariot Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible Biomark Med 4 2010 3 14
2. H. Amieva, L. Letenneur, and J.F. Dartigues et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study Dement Geriatr Cogn Disord 18 2004 87 93
3. M.S. Albert, S.T. DeKosky, and D. Dickson et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
4. H. Brodaty, M. Heffernan, and N.A. Kochan et al. Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study Alzheimers Dement 9 2013 310 317
5. E. Aretouli, K.K. Tsilidis, and J. Brandt Four-year outcome of mild cognitive impairment: the contribution of executive dysfunction Neuropsychology 27 2013 95 106
6. K. Buerger, O. Uspenskaya, and O. Hartmann et al. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment J Clin Psychiatry 72 2011 556 563
7. D.J. Devier, N. Villemarette-Pittman, and P. Brown et al. Predictive utility of type and duration of symptoms at initial presentation in patients with mild cognitive impairment Dement Geriatr Cogn Disord 30 2010 238 244
8. S.M. Landau, D. Harvey, and C.M. Madison et al. Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 2010 230 238
9. C.A. Luis, W.W. Barker, and D.A. Loewenstein et al. Conversion to dementia among two groups with cognitive impairment: a preliminary report Dement Geriatr Cogn Disord 18 2004 307 313
10. F. Maioli, M. Coveri, and P. Pagni et al. Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit Arch Gerontol Geriatr 44 2007 233 241
11. A.J. Mitchell, and M. Shiri-Feshki Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies Acta Psychiatr Scand 119 2009 252 265
12. A. Nordlund, S. Rolstad, and M. Gothlin et al. Cognitive profiles of incipient dementia in the Goteborg MCI study Dement Geriatr Cogn Disord 30 2010 403 410
13. R. Perri, L. Serra, and G.A. Carlesimo et al. Preclinical dementia: an Italian multicentre study on amnestic mild cognitive impairment Dement Geriatr Cogn Disord 23 2007 289 300
14. K. Schmidtke, and S. Hermeneit High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients Int Psychogeriatr 20 2008 96 108
15. F.E. Taragano, R.F. Allegri, and H. Krupitzki et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients J Clin Psychiatry 70 2009 584 592
16. P.N. Wang, C.J. Hong, and K.N. Lin et al. APOE epsilon4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan J Neurol Neurosurg Psychiatry 82 2011 165 169
17. A.J. Mitchell, and M. Shiri-Feshki Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis J Neurol Neurosurg Psychiatry 79 2008 1386 1391
18. O. Kohannim, X. Hua, and D.P. Hibar et al. Boosting power for clinical trials using classifiers based on multiple biomarkers Neurobiol Aging 31 2010 1429 1442
19. M. Lorenzi, M. Donohue, and D. Paternico et al. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment Neurobiol Aging 31 2010 1443 1451 1451.e1
20. I.A. van Rossum, S. Vos, and R. Handels et al. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design J Alzheimers Dis 20 2010 881 891
21. A. Maitournam, and R. Simon On the efficiency of targeted clinical trials Stat Med 24 2005 329 339
22. S.B. Hendrix Requiring an amyloid-beta1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies Alzheimers Res Ther 3 2011 10
23. S. Larrieu, L. Letenneur, and J.M. Orgogozo et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort Neurology 59 2002 1594 1599
24. F.E. Matthews, B.C. Stephan, and I.G. McKeith et al. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc 56 2008 1424 1433
25. T. Ishikawa, and M. Ikeda Mild cognitive impairment in a population-based epidemiological study Psychogeriatrics 7 2007 104
26. E.S. Blom, V. Giedraitis, and H. Zetterberg et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype Dement Geriatr Cogn Disord 27 2009 458 464
27. N. Mattsson, H. Zetterberg, and O. Hansson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
28. L.S. Schneider, R.E. Kennedy, and G.R. Cutter et al. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers Dement 6 2010 367 377
29. B. Vellas, P.S. Aisen, and C. Sampaio et al. Prevention trials in Alzheimer's disease: an EU-US task force report Prog Neurobiol 95 2011 594 600
30. ADAPT Research Group B.K. Martin, and C. Szekely et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch Neurol 65 2008 896 905
31. P.S. Aisen, S. Andrieu, and C. Sampaio et al. Report of the task force on designing clinical trials in early (predementia) AD Neurology 76 2011 280 286
32. A. Mullard Sting of Alzheimer's failures offset by upcoming prevention trials Nat Rev Drug Discov 11 2012 657 660
33. N. Coley, V. Gardette, and C. Cantet et al. How should we deal with missing data in clinical trials involving Alzheimer's disease patients? Curr Alzheimer Res 8 2011 421 433
34. G.M. Fitzmaurice, N.M. Laird, and J.H. Ware Applied longitudinal analysis 2011 Wiley Hoboken, NJ
35. L.S. Schneider, R.E. Kennedy, and G.R. Cutter Estimating power with effect size versus slope differences: Both means and variance matter Alzheimers Dement 7 2011 247
36. J.M. Leoutsakos, B.O. Muthen, and J.C. Breitner et al. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial Int J Geriatr Psychiatry 27 2012 364 374
37. B.J. Small, R.A. Dixon, and J.J. McArdle Tracking cognition-health changes from 55 to 95 years of age J Gerontol B Psychol Sci Soc Sci 66 2011 i153 i161
38. S. Piantadosi Clinical trial: a methodological perspective 2005 Wiley Hoboken, NJ
39. A. Cnaan, N.M. Laird, and P. Slasor Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data Stat Med 16 1997 2349 2380
40. R.E. Kennedy, L.S. Schneider, and G.R. Cutter Biomarker positive and negative subjects in the ADNI cohort: clinical characterization Curr Alzheimer Res 9 2012 1135 1141
41. P. Chen, G. Ratcliff, and S.H. Belle et al. Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study Arch Gen Psychiatry 58 2001 853 858
42. ADAPT Research Group C.L. Meinert, and L.D. McCaffrey et al. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results Alzheimers Dement 5 2009 93 104
43. K.M. Hayden, A.S. Khachaturian, and J.T. Tschanz et al. Characteristics of a two-stage screen for incident dementia J Clin Epidemiol 56 2003 1038 1045
44. R. Brookmeyer, S. Gray, and C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337 1342
45. E.L. Teng, and H.C. Chui The Modified Mini-Mental State (3MS) Examination J Clin Psychiatry 48 1987 314 318
46. R Development Core Team R: a language and environment for statistical computing 2011 R Foundation for Statistical Computing Vienna, Austria
47. E.L. Abner, B.C. Dennis, and M.J. Mathews et al. Practice effects in a longitudinal, multi-center Alzheimer's disease prevention clinical trial Trials 13 2012 217 224
48. G.M. Terrera, C. Brayne, and F. Matthews et al. One size fits all? Why we need more sophisticated analytical methods in the explanation of trajectories of cognition in older age and their potential risk factors Int Psychogeriatr 22 2010 291 299
49. L. Wu, P. Rosa-Neto, and S. Gauthier Use of biomarkers in clinical trials of Alzheimer disease: from concept to application Mol Diagn Ther 15 2011 313 325
50. M.M. Mielke, P.P. Zandi, and H. Shao et al. The 32-year relationship between cholesterol and dementia from midlife to late life Neurology 75 2010 1888 1895
51. S.J. Pocock, S.E. Assmann, and L.E. Enos et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems Stat Med 21 2002 2917 2930